Drug prescribing practices for tuberculosis in Uzbekistan

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 11, 2009, Pages 1405-1410

  Hasker, E ^a,b   Khodjikhanov, M ^a   Usarova, S ^a   Asamidinov, U ^a   Yuldashova, U ^a   Van Der Werf, M J ^c,d   Uzakova, G ^e   Veen, J ^a  

^a Tuberculosis Control Programme for the Central Asia Region   (Uzbekistan)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Project Implementation Unit   (Uzbekistan)

Author keywords

Drug therapy; Prevention and control; Tuberculosis

Indexed keywords

AMINOCAPROIC ACID; AMINOPHYLLINE; AMPICILLIN; ASCORBIC ACID; CALCIUM CHLORIDE; CYANOCOBALAMIN; DEXTRAN DERIVATIVE; DIPHENHYDRAMINE; DIPYRONE; EMODIN; ETHAMBUTOL; GLUCONATE CALCIUM; GLUCOSE; IMMUNOMODULIN; INFESOL; ISONIAZID; PENICILLIN G; PROCAINE; PYRAZINAMIDE; PYRIDOXINE; REOPOLYGLUKIN; RIBOXIN; RIFAMPICIN; SODIUM CHLORIDE; STREPTOMYCIN; SULFOCAMFOCAINE; THIAMINE; THYMUS EXTRACT; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ADULT; AGED; ALOE; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; GLUCOSE INFUSION; HEALTH CARE PRACTICE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RANDOM SAMPLE; SHORT COURSE THERAPY; TUBERCULOSIS; UZBEKISTAN; ADOLESCENT; CLINICAL PRACTICE; DRUG COMBINATION; DRUG UTILIZATION; ECONOMICS; EVIDENCE BASED MEDICINE; MIDDLE AGED; PRACTICE GUIDELINE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DRUG COSTS; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TUBERCULOSIS; UZBEKISTAN; YOUNG ADULT;

EID: 73949120925     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.1313. Geneva, Switzerland: WHO, 2003.
2. World Health Organization. Anti-tuberculosis drug resistance in the world, 4th global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
3. Cox H S, Orozco J D, Male R, et al. Multidrug-resistant tuberculosis in central Asia. Emerg Infect Dis 2004; 10: 865-872.
4. Espinal M, Frieden T. What are the causes of drug-resistant tuberculosis? In: Frieden T, ed. Toman's tuberculosis: case detection, treatment, and monitoring\questions and answers. 2nd ed. Geneva, Switzerland: World Health Organization, 2004: pp 72-79.
5. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
6. Bloom B S. Daily regimen and compliance with treatment. Fewer daily doses and drugs with fewer side effects improve compliance [Editorial]. BMJ 2001; 323: 647.
7. Diop A H, Gakiria G, Pande S B, Malla P, Rieder H L. Dosages of anti-tuberculosis medications in the national tuberculosis programs of Kenya, Nepal and Senegal. Int J Tuberc Lung Dis 2002; 6: 215-221.
8. Thompson N P, Caplin M E, Hamilton M I, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388.
9. Thomas R J. Neurotoxicity of antibacterial therapy. South Med J 1994; 87: 869-874.
10. Russo P A, Chaglasian M A. Toxic optic neuropathy associated with ethambutol: implications for current therapy. J Am Optom Assoc 1994; 65: 332-338.
11. Trébucq A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Int J Tuberc Lung Dis 1997; 1: 12-15.
12. Ormerod L P, Horsf eld N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle Lung Dis 1996; 77: 37-42.
13. Jacobs B, Clowes C, Wares F, et al. Cost-effectiveness analysis of the Russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia. Int J Tuberc Lung Dis 2002; 6: 396-405.
14. Perelman M I, Koryakin V A, Bogadelnikova I V. Treatment of tuberculosis patients. In: Phthysiology. 3rd ed. Moscow, Russia: Medicina, 2004: pp 473-475.
15. Snider D E. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61: 191-196
16. Merck. The Merck manuals online medical library. Whitehouse Station, NJ, USA: Merck. http://www.merck.com/mmpe/index/ind-ca.html Accessed June 2009.
17. Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Current Pharmaceutical Design 2004; 10: 3297-3312.
18. World Bank. Key development data and statistics. Washington DC, USA: World Bank, 2009. http://web.worldbank.org/W BSITE/EXTERNAL/DATASTATISTICS/0, contentMDK:20 535285~menuPK:1192694~pagePK:64133150~piPK:641331 75~theSitePK:239419,00.html Accessed June 2009.